CIGNA Co. (NYSE:CI) Director Jane E. Md Henney sold 400 shares of CIGNA stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $212.96, for a total value of $85,184.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of CIGNA Co. (NYSE CI) opened at $219.66 on Friday. The company has a quick ratio of 0.39, a current ratio of 0.39 and a debt-to-equity ratio of 0.37. CIGNA Co. has a 52 week low of $133.52 and a 52 week high of $221.13. The firm has a market capitalization of $54,329.69, a P/E ratio of 24.06, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51.
CIGNA (NYSE:CI) last issued its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.36 by $0.47. CIGNA had a return on equity of 18.85% and a net margin of 5.74%. The company had revenue of $10.38 billion during the quarter, compared to analysts’ expectations of $10.17 billion. During the same quarter in the previous year, the business earned $1.94 earnings per share. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. equities research analysts expect that CIGNA Co. will post 10.34 EPS for the current year.
Several brokerages have recently issued reports on CI. Royal Bank of Canada reiterated an “outperform” rating and issued a $220.00 price objective (up previously from $185.00) on shares of CIGNA in a research note on Friday, November 3rd. Credit Suisse Group began coverage on CIGNA in a research note on Thursday, November 2nd. They issued an “outperform” rating and a $219.00 price objective for the company. Goldman Sachs Group began coverage on CIGNA in a research note on Wednesday, January 3rd. They issued a “neutral” rating and a $247.00 price objective for the company. Morgan Stanley lifted their price objective on CIGNA from $195.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Finally, Jefferies Group lifted their price objective on CIGNA from $201.00 to $221.00 and gave the company a “buy” rating in a research note on Friday, October 13th. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $205.18.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/01/19/cigna-co-ci-director-sells-85184-00-in-stock.html.
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.